Patel Naimish 4

What Happened
Naimish Patel, Chief Medical Officer of CRISPR Therapeutics (CRSP), had 10,000 restricted stock units (RSUs) convert into common shares on May 28, 2026. Following the vesting/conversion, 3,786 of those shares were sold in an open-market transaction on May 29, 2026 at $55.62 per share, generating $210,577. The sale was executed to satisfy tax withholding obligations under the company’s RSU settlement policy, not as a discretionary trade.

Key Details

• Transaction dates and prices:
  • 2026-05-28: RSU conversion/exercise of derivative for 10,000 shares (acquired; price N/A).
  • 2026-05-29: Open-market sale of 3,786 shares @ $55.62 = $210,577.
• Shares owned after transaction: not specified in the Form 4 filing.
• Footnotes:
  • F1: Each RSU equals a right to one share of CRSP common stock.
  • F2: The 3,786-share sale was required to cover tax withholding per the company RSU Settlement Policy (not discretionary).
  • F3: The RSU award was granted May 28, 2024 for 40,000 shares with quarterly vesting through May 28, 2028.
• Filing timeliness: Form 4 was filed on 2026-06-01 for a May 28 transaction; this appears to be timely (filed within the standard two business days).

Context
This was a routine post-vesting transaction: RSUs vested and converted to shares, and a portion was sold immediately to meet tax-withholding requirements (a common, non-discretionary practice). Such mandated sales are generally not considered a strong signal about an insider’s view of the company’s prospects.